RCT: nevirapine vs. efavirenz for patients co-infected with HIV and tuberculosis
Source: Lancet Infectious Diseases
Area: News
Nevirapine and efavirenz are widely used as antiretroviral therapy in countries with high incidence of HIV and tuberculosis co-infection but both drugs interact with antituberculosis drugs. The authors of a study, published online in Lancet Infectious Diseases, compared the efficacy and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an efavirenz-based regimen in co-infected patients receiving antituberculosis medication.
The study was a multicentre, open-label, non-inferiority trial conducted at three health centres in Mozambique. Patients were randomised in a 1:1 ratio to receive nevirapine 200 mg twice daily (n = 242) or efavirenz 600 mg once daily (n = 233), plus lamivudine and stavudine. The primary endpoint was virological suppression at 48 weeks (HIV-1 RNA <50 copies per mL). The non-inferiority margin for the difference of efficacy was 10%.
The authors reported the following findings:
. In the ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Health | Infectious Diseases | Mozambique Health | Study | Tuberculosis | Virology